The investigational ZORYVE foam 0.3% shows significant improvements in patient-reported quality of life and symptom relief for individuals with psoriasis, indicating its potential as a valuable ...

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

Poster Number 62155 Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis: Improvements in Patient-Reported Outcomes (ARRECTOR) Gooderham, M et al. ZORYVE cream, 0.3%, is indicated for ...

ZORYVE foam significantly improved quality ... Individuals reported an improvement in symptoms as well as a reduction in how psoriasis impacted their daily life (e.g., embarrassment, stress ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15% ...

Zoryve (roflumilast) is a prescription drug that’s used to treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in adults and certain children. Zoryve comes as a topical cream or ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new data from two posters ...

The third risk to consider would be in terms of the sNDA that was submitted to the FDA for the expansion of the label of ZORYVE foam to treat patients with scalp and body psoriasis. The FDA ...

“Highlighting additional data from our clinical development program for ZORYVE foam in scalp and body psoriasis and ZORYVE cream in atopic dermatitis reinforces the strong need for well ...

Vtama and Zoryve have different mechanisms of action, but are lumped together into the newer novel agents class that are indicated for all levels of severity in psoriasis. Unlike traditional ...